Administrative Rules of Montana
Department 37 - PUBLIC HEALTH AND HUMAN SERVICES
Chapter 37.57 - MATERNAL AND CHILD HEALTH
Subchapter 37.57.3 - Infant Screening Tests and Eye Treatment
Rule 37.57.301 - DEFINITIONS

Universal Citation: MT Admin Rules 37.57.301

Current through Register Vol. 18, September 20, 2024

As used in this subchapter, the following definitions apply:

(1) "Health care facility" means a hospital or other facility licensed by or located in the state of Montana for the purpose of providing health care services, and which provides primary health care services for newborns at birth.

(2) "Newborn" means an infant in the first 28 days of life.

(3) "Newborn screening tests" are screening tests, procedures, or both for the following conditions:

(a) Acylcarnitine Disorders:
(i) Fatty Acid Oxidation Disorders:
(A) Carnitine uptake defect;

(B) Long-chain L-3-OH acyl-CoA dehydrogenase deficiency;

(C) Medium-chain acyl-CoA dehydrogenase deficiency;

(D) Trifunctional protein deficiency; and

(E) Very long-chain acyl-CoA dehydrogenase deficiency;

(ii) Organic Acidemia Disorders:
(A) 3-hydroxy-3-methylglutaryl-CoA lyase deficiency;

(B) 3-Methylcrotonyl-CoA carboxylase deficiency;

(C) [BETA]-ketothiolase deficiency;

(D) Glutaric acidemia type I;

(E) Isovaleric acidemia;

(F) Methylmalonic acidemia (Cbl A,B);

(G) Methylmalonic acidemia (mutase deficiency);

(H) Multiple carboxylase deficiency; and

(I) Propionic acidemia;

(b) Amino Acid Disorders:
(i) Argininosuccinic acidemia;

(ii) Citrullinemia type 1;

(iii) Homocystinuria;

(iv) Maple syrup urine disease;

(v) Classic Phenylketonuria; and

(vi) Tyrosinemia type I;

(c) Biotinidase deficiency;

(d) Classical galactosemia;

(e) Congenital adrenal hyperplasia;

(f) Primary congenital hypothyroidism;

(g) Cystic fibrosis;

(h) Hemoglobinopathies, including:
(i) Hb S/[BETA] -thalassemia;

(ii) Hb SC disease; and

(iii) Hb SS disease; and

(i) Critical congenital heart disease, including:
(i) hypoplastic left heart syndrome;

(ii) pulmonary atresia;

(iii) tetralogy of Fallot;

(iv) total anomalous pulmonary venous return;

(v) transposition of the great arteries;

(vi) tricuspid atresia;

(vii) truncus arteriosus;

(j) Severe combined immunodeficiency disease;

(k) Spinal muscular atrophy (SMA); and.

(l) X-linked adrenoleukodystrophy (X-ALD).

AUTH: 50-19-202, MCA; IMP: 50-19-203, MCA

Disclaimer: These regulations may not be the most recent version. Montana may have more current or accurate information. We make no warranties or guarantees about the accuracy, completeness, or adequacy of the information contained on this site or the information linked to on the state site. Please check official sources.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.